Abstract Details

Title Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) S19 - Aging and Dementia (2:32 PM-2:40 PM)

Poster/Presentation
Number 004

Objective To determine whether estrogen modulating therapy (EMT) exposure impacts risk of neurodegenerative disease (NDD) in women with breast cancer.

Background The association between EMT exposure for breast cancer treatment and neurodegenerative disease (NDD) is unclear. The mechanism of EMT action in CNS remains to be fully established.

Design/Methods This retrospective cohort study used Humana 2007-2017 claims dataset. Patient claims records were surveyed for diagnosis of NDD starting 6 months post breast cancer diagnosis for the duration of enrollment in the claims database. Humana dataset contains claims from private-payer and Medicare insurance datasets from across the United States. Patients receiving EMT for breast cancer treatment were identified. Survival analysis was used to determine the association between EMT exposure and diagnosis of NDD in the post index date follow-up period. A propensity score approach was used to minimize measured and unmeasured selection bias.

Results In this cohort study of 57,843 propensity score matched perimenopausal to postmenopausal aged women with breast cancer, estrogen modulating therapy exposure was associated with significant decrease in diagnosis of neurodegenerative disease, most specifically Alzheimer’s disease (RR, 0.827; 95%CI, 0.759-0.901; P < .0001). Kaplan-Meier curves for NDD-free survival were analyzed to determine overall rate and proportion of patients in each treatment group who developed neurodegenerative disease. Outcomes of these analyses indicate reduction of NDD-risk increased with age.

Conclusions

Among patients with breast cancer, tamoxifen and steroidal aromatase inhibitors were associated with decreased risk for diagnosis of NDD, specifically Alzheimer's Disease and Dementia. Investigation of molecular mechanisms by which EMT protects against AD and Dementia are ongoing.

Authors/Disclosures
Gregory L. Branigan, PhD PRESENTER	Dr. Branigan has nothing to disclose.
Gregory L. Branigan, PhD	Dr. Branigan has nothing to disclose.
	No disclosure on file
Roberta Diaz Brinton, PhD (University of Arizona)	Roberta Diaz Brinton, PhD has nothing to disclose.

��ɫ��

��ɫ��